Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Fox Chase Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019
Estimated time to complete: 1 hour and 30 minutes

This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


Instructions for Earning CE credit

This activity has expired, credit is no longer available.




 

Quick Tips

What is the appropriate use of new agents for mantle cell lymphoma?
What is the potential of emerging therapies?
What are the current treatments for relapsed/refractory DLBCL?
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.